HiberGene Announces First Product Sales and Appointment of Distributors Distribution Network Covers Europe, Middle East and Africa


HiberGene Announces First Product Sales and Appointment of Distributors Distribution Network Covers Europe, Middle East and Africa

Dublin, Ireland 1 March 2016 ... HiberGene Diagnostics, a company focused on the application of molecular technology to infectious disease testing, has made its first product sales, and has secured a number of distributors across Europe, Middle East and Africa.

HiberGene made its first product shipments in December 2015, and has appointed distributors in a number of countries across Europe, Middle East and Africa. These territories include Germany, Austria, Spain, Portugal, Ireland, Poland, Hungary, Sweden, Denmark, Norway, Finland, Turkey, Israel and South Africa. HiberGene is also in discussion with potential distributors in Italy, UK, France, Belgium, Netherlands, Greece, China, India, Saudi Arabia, Australia, South Korea, Taiwan, Singapore and Malaysia.

Brendan Farrell, CEO of HiberGene, said: "Our first product shipment is a significant step for HiberGene. With our expanding network of distributors and our planned launch of three further products in 2016, we are well positioned to exploit the full commercial potential of our technology. With the HG Meningococcus test now launched, and the Group B Streptococcus test preparing for launch in Q2 of this year, coupled with two further tests to be launched in 2016, we have a strong and growing portfolio of tests to meet a range of unmet clinical needs for human infectious diseases."

There have been a number of significant developments for HiberGene since 2014. These include HiberGene securing its Series A financing of €2.1 million, close of the first tranche of a Series B Financing of €1.5 million, and the CE Marking and launch of its HG Meningococcus and HG Swift Instrument. In addition, the company made a number of key appointments, and moved into new facilities.


For more information, please contact:

Tony Stephenson                                                                    Brendan Farrell
Exitus Communications                                                                       Chairman & CEO
Tel: +44 (0)7899 796655                                                    HiberGene Diagnostics Limited
Email: tony@exituscommunciations.co.uk         Email: brendan.farrell@hibergene.com
Notes to Editors:
HiberGene is a diagnostics company focussed on applying molecular technology to the infectious disease segment of the diagnostic market. Utilising the LAMP platform, HiberGene has developed rapid and highly sensitive diagnostic tests for Meningitis and Group B Streptococcus, which can be used in almost any clinical or laboratory setting. HiberGene also intends to develop a series of additional tests for use in detecting human infectious diseases.
HiberGene has received Advanced Assurance that it qualifies for the Enterprise Investment Scheme (EIS) for individual investors to obtain tax refunds and other benefits as a consequence of investing in HiberGene.